Aug 31, 2022 / 12:00PM GMT
Operator
Good morning, and welcome to ImmunoGen's Pivek Program Update Conference Call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
Anabel Chan -
Good morning, and thank you for joining this call.
Earlier today, we issued a press release announcing an update to our pivotal Phase II CADENZA study of Pivekimab Sunirine and BPDCN. This press release and a recording of this call can be found under the Investors and Media section of our website at ImmunoGen.com.
With me today are Mark Enyedy, our President and CEO; and Anna Berkenblit, our Chief Medical Officer; Theresa Wingrove, our Head of Regulatory Affairs and Quality; Kristen Harrington-Smith, our Chief Commercial Officer; and Susan Altschuller, our Chief Financial Officer, will also join us for Q&A.
We will be making forward-looking statements based on our current expectations and beliefs. These statements include those related to the progression of our CADENZA study and the timing of
ImmunoGen Inc to Provide Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm Call Transcript
Aug 31, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers